Mod­er­na CEO brush­es off US sup­port for IP waiv­er, eyes more than $19B in Covid-19 vac­cine sales in 2021

Mod­er­na is de­fin­i­tive­ly more con­cerned with keep­ing pace with Pfiz­er in the race to vac­ci­nate the world against Covid-19 than it is with Wednes­day’s de­ci­sion from the Biden ad­min­is­tra­tion to back an in­tel­lec­tu­al prop­er­ty waiv­er that aims to in­crease vac­cine sup­plies world­wide.

In its first quar­ter earn­ings call on Thurs­day, Mod­er­na CEO Stéphane Ban­cel shrugged off any sug­ges­tion that the new­ly US-backed in­tel­lec­tu­al prop­er­ty waiv­er would im­pact his com­pa­ny’s vac­cine or bot­tom line. Still, the com­pa­ny’s stock price fell by about 9% in ear­ly morn­ing trad­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER